EMA's SME Office Highlights Positive Drug Approval Trends

LONDON  Biotechs registered with the SME (small- and medium-sized enterprise) Office of the European Medicines Agency (EMA) have seen consistent improvements in the success rate of applications for marketing approvals, according to a report analyzing activity in the seven years since the office was set up in 2005.

To continue reading subscribe now to BioWorld Asia (formerly International)